Valuation IDEXX Laboratories, Inc.
Stocks
IDXX
US45168D1046
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 556.20 USD | +2.18% |
|
-1.98% | -17.79% |
| 07-27 | Elanco Seems Best-Positioned Into Q2 Print Among Animal Health Stocks, UBS Says | MT |
| 07-27 | UBS Cuts IDEXX Laboratories Price Target to $620 From $640, Maintains Neutral Rating | MT |
Company Valuation: IDEXX Laboratories, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 55,833 | 33,786 | 46,098 | 33,854 | 54,022 | 42,938 | - | - |
| Change | - | -39.49% | 36.44% | -26.56% | 59.57% | -20.52% | - | - |
| Enterprise Value (EV) 1 | 56,612 | 35,022 | 46,592 | 34,434 | 54,690 | 43,074 | 42,535 | 42,208 |
| Change | - | -38.14% | 33.04% | -26.09% | 58.83% | -21.24% | -1.25% | -0.77% |
| P/E | 76.6x | 50.8x | 55.2x | 38.7x | 51.7x | 37.1x | 32.9x | 29x |
| PBR | 82.6x | 55.6x | 31x | 21.6x | 34.1x | 20.6x | 15.1x | 11.4x |
| PEG | - | -7.66x | 2.2x | 6.38x | 2.3x | 3.1x | 2.6x | 2.2x |
| Capitalization / Revenue | 17.4x | 10x | 12.6x | 8.69x | 12.6x | 9.12x | 8.39x | 7.69x |
| EV / Revenue | 17.6x | 10.4x | 12.7x | 8.83x | 12.7x | 9.15x | 8.32x | 7.56x |
| EV / EBITDA | 54.6x | 34.7x | 38.4x | 28.1x | 36.3x | 25.7x | 23x | 20.7x |
| EV / EBIT | 60.7x | 39x | 42.5x | 30.5x | 40.2x | 28.3x | 25.3x | 22.5x |
| EV / FCF | 89x | 88.9x | 60.3x | 42.6x | 51.7x | 37.2x | 32.9x | 29x |
| FCF Yield | 1.12% | 1.13% | 1.66% | 2.35% | 1.93% | 2.69% | 3.04% | 3.45% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 8.6 | 8.03 | 10.06 | 10.67 | 13.08 | 14.66 | 16.54 | 18.75 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 3,215 | 3,367 | 3,661 | 3,898 | 4,304 | 4,708 | 5,115 | 5,581 |
| EBITDA 1 | 1,037 | 1,011 | 1,212 | 1,225 | 1,505 | 1,679 | 1,845 | 2,042 |
| EBIT 1 | 932 | 898.8 | 1,097 | 1,128 | 1,360 | 1,520 | 1,683 | 1,879 |
| Net income 1 | 744.8 | 679.1 | 845 | 887.9 | 1,059 | 1,169 | 1,302 | 1,461 |
| Net Debt 1 | 779.2 | 1,236 | 493.9 | 579.3 | 667.8 | 136 | -403 | -730 |
| Reference price 2 | 658.46 | 407.96 | 555.05 | 413.44 | 676.53 | 544.32 | 544.32 | 544.32 |
| Nbr of stocks (in thousands) | 84,794 | 82,817 | 83,052 | 81,885 | 79,851 | 78,883 | - | - |
| Announcement Date | 2/2/22 A | 2/6/23 A | 2/5/24 A | 2/3/25 A | 2/2/26 A | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- IDXX Stock
- Valuation IDEXX Laboratories, Inc.
Select your edition
All financial news and data tailored to specific country editions
